in this securities class action,plaintiff mississippi public employees retirement system alleges that senior management of boston scientific corporation bsc,a publicly traded manufacturer of medical devices in which plaintiff invested,withheld material information and made misleading statements in violation of sections b and a of the securities exchange act of,b,a,and securities exchange commission rule,b.
in an earlier opinion,we reversed a rule b dismissal of plaintiff complaint,finding that the inference of scienter advanced by the plaintiff was at least as cogent and compelling as the contrary inference,satisfying the strong inference pleading standard of the private securities litigation reform act.see.pub.emps.ret.boston scientific bsc i,cir.after the district court permitted discovery,the defendants filed a motion for summary judgment,testing whether the evidence,and not merely the allegations,withstood scrutiny.the district court found that the evidence did not and granted defendants motion.see in re boston sci.sec,d.the plaintiff appealed,and as is common in litigation,the shape of the case has changed since we last reviewed it.
plaintiff central claim is that defendants were aware that bsc would likely need to implement a significant recall of its taxus express paclitaxel eluting coronary stent system taxus,and that through affirmative statements and omissions,defendants intentionally or recklessly misled the investing public about the existence,cause,and degree of this risk.as to omissions,plaintiff argues that starting in november,defendants chose not to disclose or implement a manufacturing solution to a problem with taxus because doing so would have caused a delay in the fda approval of the device.this,in turn,would have hampered bsc business strategy of building up sufficient taxus inventory to flood the market upon its launch.as to affirmative statements,plaintiff claims that defendants lulled the market by repeatedly saying that the problems were due to doctor inexperience with the stent system,rather than manufacturing,and that recalls were unlikely.
the district court found that on the undisputed facts,drawing all inferences in plaintiff favor,no reasonable jury could find sufficient evidence of three key elements of securities fraud we affirm on the sole ground that plaintiff has failed to produce evidence that would permit a reasonable inference that defendants acted with scienter.
we assume some familiarity with our prior opinion and focus on the facts and claims that are key to this appeal.
stent systems 
in treating coronary artery disease,clogged arteries,physicians often use stents in angioplasty procedures as an alternative to open heart surgery.a stent delivery system consists of three central components a catheter,which is a long hollow plastic tube used to guide the stent along the inside of the arteries,a balloon that is laser welded to the end of the catheter,and the stent itself,which is crimped or collapsed on the deflated balloon.during an implant procedure,the balloon is inflated,which expands and deploys the stent and clears the blockage.after the stent is deployed and apposed to the artery wall,the balloon is deflated and withdrawn.
bsc makes two different stent systems.there is the taxus system,on which plaintiff claims rest,and the express,which is very similar to taxus.the primary difference between them is that the stent in the taxus system is coated with a polymer containing a drug to ease complications associated with stent implant,while the stent in the express system is not coated.both the express and taxus systems are built using the same express catheter.
b.the express system 
we begin with an overview of the express system and bsc gradual improvement of it,as this background is necessary to understand the nature and basis of the plaintiff claims about taxus.bsc improvements to the express system can be categorized into three phases on the undisputed evidence.
express phase one reducing process variability 
bsc began selling the express system outside the united states in june,and received fda approval for sales in september.the system was manufactured at company facilities in maple grove,minnesota,and galway,ireland.
in early,bsc received reports of complaints that the balloon on express devices had not deflated,including from the same manufacturing lot.while bsc had received occasional complaints of this problem since the product launch,the increased rate and the existence of multiple from the same batch caused bsc to conduct an inquiry.lots meant that the problem was not dispersed throughout all devices,and consequently that the normal method of calculating frequency did not apply.
bsc initiated a site level correction action slca at maple grove led by paul weiss,and a corresponding corrective and preventative action capa at galway led by niamh.slca and capa investigations are commenced to investigate issues that are systemic or could disrupt business operations.as part of their investigations,paul weiss and niamh opened a product inquiry report pir.a pir is used to investigate and make recommendations for actions or field actions to bsc field action committee fac,which has ultimate responsibility for instituting field actions such as recalls.although the complaints were about express,taxus which was only being sold outside the united states at the time was included in the pir because both systems were built using the same express catheter.
on may,the pir team issued a report on the primary cause of the problem.the team found that the problem was due to a condition known as focal necking or focal neckdown,where the distal outer the portion of the catheter that is welded to the balloon becomes elongated or stretched,preventing the withdrawal of the fluid used to inflate the balloon.the team further found that this focal necking had two primary causes excessive heat at the laser bond of the balloon and the distal outer,which could be caused by a laser that was too hot or misaligned,and a subsequent excessive tensile force exerted in the area of the bond,which could occur either during or after manufacturing.
while the team could not identify the specific cause of the tensile force,it was able to identify several actions to prevent or lessen the incidence of focal necking.to address issues with the laser weld,it recommended reducing the laser energy settings,increasing the magnification of the alignment camera,and retraining operators.for the same reason,the team also recommended using only distal outers manufactured in maple grove,which were found to be more robust than those manufactured in galway,and launching an investigation to understand why the galway distal outers appeared more prone to focal necking.
the pir team also reported on the frequency of the issue.for express devices manufactured in galway,it found twenty out of over revenue shipments,with two lots producing three complaints each for those manufactured in maple grove,it found only one for taxus devices,which were only manufactured in galway at the time,it found zero out of over revenue shipments.given this low rate of occurrence combined with the limited severity in all but one case,the pir team concluded that n o field action is recommended at this time.
the team was asked at a may meeting to determine the scope of the issue in case a recall was needed,and it found no factors that could be used to identify some devices as being.it considered data on numerous parameters of the focally necked devices including laser weld,elongation,type of resin used,and extrusions but found no correlations from which to scope the problem.on may,the team issued a pir with the same conclusions and recommendations that it had reached in the may report.
on may,the fac accepted the pir team recommendations and conclusions.it agreed that a recall was not warranted at the time,finding that the product in the field was within all of its established specifications,the frequency of issues reported from the field were extremely low,and the consequences,while potentially severe in some cases are not outside those expected with this type of procedure.the chairman of the fac,paul sandman,later testified that the fac did not institute a recall because there were any factors that indicated that these failures were caused by a manufacturing problem.
the fac also directed that the pir be clarified to state that the issue involves units within specification,and indistinguishable from a visual standpoint,being subjected in the field to a level of tensile force exceeding that for which the product was designed.it is unclear whether this was meant to supplement,or replace,the pir statement that the tensile event may have also occurred during manufacturing 
in implementing the pir team suggestions,bsc sought to harmonize the robustness of the stent systems produced at galway with those produced at maple grove.the changes focused on the properties of the distal outers and the proximal welding process.as to the proximal welding process,bsc increased the magnification used to line up the stent system components,making it identical with that in maple grove,and retrained the galway operators on the proper alignment of the laser weld and the proper handling of the catheters to avoid tensile forces on the product.these changes were implemented in may.as to the quality of the distal outers,galway immediately switched to using maple grove distal outers in its production and over the following three months,bsc implemented various changes to harmonize the manufacturing of distal outers at the facilities,including aligning their elongation testing equipment,extrusion parameters,and distal outer measurement methods.bsc also introduced changes to ensure that the area of the proximal weld was not exposed to excessive heat during laser welding,including implementing an manufacturing acceptance criterion for the length of the weld the matte finish length 
because none of these changes affected device design or performance specification,bsc determined that prior fda approval was not required,and implemented them in accordance with its standard bsc quality system procedures.
express phase two a new design specification 
although bsc determined that a recall was not necessary,it nevertheless decided to further investigate the issue.internal correspondence from this period shows that the issue was seen by some in the company as urgent and a severe compliance risk.so in galway,a six sigma team was initiated on may,to investigate the cause of focal necking in addition,following up on the capa investigation finding that the material properties of the distal outer shaft could contribute to the robustness of the proximal balloon weld,bsc created a team in maple grove where the distal outer shafts had been found to be more robust to develop a new design specification for the distal outer.
over the next four months,the maple grove team developed a proposal that focused on the elongation properties of the distal outer.elongation served as an indirect measure of the molecular orientation and crystallinity of the polymer material used in the distal outer.by setting a length that the distal outer could be stretched before breaking,bsc aimed to ensure that each of its distal outers had material properties that would increase its robustness to subsequent thermal processing that occurs when the outer is laser welded to the balloon component of the delivery system.
on october,bsc filed a supplement to its express premarket approval pma with the fda,seeking permission to implement a test method to evaluate the elongation property of the extruded distal outer shaft component for the express.in this document,bsc stated that the change was meant to address complaints.bsc disclosed that it had received a small number of field complaints approximately complaint rate regarding the delivery system balloon failure to deflate and provided a table listing the by month and manufacturing site for january through august.it explained that although it had been unable to definitively confirm the root cause of the failure,its investigation had determined that at least part of the root cause is due to inconsistent material properties of the distal outer shaft component,and that the new design specification was intended to improve the robustness of the distal outer shaft,and to improve the consistency between distal outer shafts manufactured at bsc maple grove and galway facilities.
finally,bsc notified the fda in this supplement of all of the may corrective actions that it had taken,explaining its determination that these changes did not require fda approval.it also reported on the success of these measures,noting that the fifteen complaints for express devices that it had received between may and august were for devices built prior to the implementation of the changes.
the fda approved bsc request on october.
express phase three reticle inspection 
and laser shift 
at the same time that bsc was implementing the elongation specification,the six sigma team was completing its report on the laser shift.it found that by shifting the location of the laser used to bond the balloon to the distal outer,from mm to mm,focal necking would be prevented,regardless of the settings of the other factors.however,as peter delmer,who headed the effort in galway,stated,an awful lot more work would have to be done in order to implement that solution.the company needed to verify that the change would not introduce new problems and also confirm whether mm was the ideal position,or whether mm would be better.
this validation work was assigned to kevin griffin,a process development engineer at maple grove.on september,griffin created a plan estimating that a proposal could be submitted to the fda in november.however,he stated even at this time that the plan was a bit optimistic.his team was advised to keep those working on taxus,a different group,informed because any manufacturing change submitted to the fda would need to be assessed for its impact to the taxus pma.in the following months,the team worked to develop a validation protocol,which involved discussions with various branches of the company,including manufacturing and regulatory.
at this point,as of the beginning of the class period in november,there had been only two complaints for the tens of thousands of express and taxus devices manufactured at galway after the introduction of the may changes,and there had been only three ever on express devices manufactured at maple grove.consequently,paul weiss,the leader of the pir,concluded on november,that the interim actions have been very effective.
c.the taxus system 
during this time period,bsc was also working to have taxus approved for sale in the united states,after having distributed it outside the united states since february.it established a taxus pma council,which oversaw the filing of five separate modules to the fda between february and june and continued to meet throughout the summer to monitor the pma progress and amendments.
on october,the taxus pma council decided that no additional manufacturing changes to the taxus pma would be submitted after october unless they were considered critical and approved by the council,as these changes could jeopardize the fda review of the taxus pma.the taxus council was aware that a separate team of engineers was also working on a laser shift for the express catheter,but did not consider the laser shift to be critical.paul weiss testified that the evidence at that time was we had corrected the issue and that the laser shift was merely seen as a preventive action to make the product more robust to focal necking.
on november,the first day of the class period,a company press release announced that the fda circulatory devices panel would recommend that taxus be approved for sale in the united states.bsc ramped up taxus production in anticipation for the launch.
it is important to note that the units being manufactured for the launch incorporated the october distal outer elongation specification,as well as a new manufacturing process known as cone puffing,which had not been used on the units produced for sale outside the united states.cone puffing involves inflating one cone of the balloon so that it goes over one end of the stent.this technique was implemented to better secure the stent placement on the device,preventing the stent from becoming dislodged during implantation.there is no evidence that anyone at this point suspected or had reason to suspect that cone puffing could contribute to focal necking.
in the following months,research on validating the laser shift continued.a december,memo from kevin griffin reported that although the team had learned a lot about what affects focal necking,there is still uncertainty due to test method repeatability,other known contributors like heat shrink that are not well understood yet,and the underlying polymer science is still being investigated.he stated that on an aggressive research time frame,validation could be completed by february.
on march,the fda approved taxus for sale in the united states,and within the first couple of weeks following the launch,boston scientific received about a dozen complaints on taxus but not express units manufactured in galway and in maple grove.this included multiple complaints for two taxus manufacturing lots.bsc initiated a worldwide focal necking operations team to investigate the failures and determine whether any lots had a higher propensity to focally neck.
while the team was ultimately unable to identify any such lots,the of this team issued a memo on march suggesting that bsc add a criterion for the minimum outer diameter minod of the distal outer at the location of the laser weld to eliminate the subjective nature of prior visual inspections,and add an inspection to measure the minod to ensure that it met the criterion.the memo also noted that based on simulations with surgeons,it appeared that surgeons were not exerting the degree of tensile force on the devices that would be necessary to cause the necking.it concluded we do know where in our processing the tensile forces are occurring to cause the focal neck the loading of the balloon protector after folding and after cone puffing has been highly suspected,but we have not been able to draw a direct correlation to focal necking.
two days later,on march,bsc received notice that one hospital in which a had required surgical removal of the stent decided to cease using taxus at all of its facilities until it had determined whether this was an isolated incident or a product defect.
at the end of march,the design,testing,and validation work on the laser shift for both express and taxus was completed.on april,bsc submitted a special pma supplement to the fda for its taxus and express systems.bsc requested permission to shift the laser so that it was mm,instead of mm,from the edge of the overlap between the balloon and the distal outer add a criterion for the minod of the distal outer at the location of the laser weld to eliminate the subjective nature of prior visual inspections and add an inspection to measure the minod to ensure that it met the criterion.
as the minod was determined to be important independent of the laser shift,bsc also added a reticle inspection to measure the minod,which did not require fda approval and was implemented on april.the reticle inspection involved a magnification tool with guidelines to assist in measuring the bond width,because bonds of a certain minimum width were found to be robust against focal necking regardless of the location of the laser.
on april,the fda contacted bsc to schedule a teleconference and to express concern regarding a type of complaint regarding taxus that bsc had not yet addressed to the fda in any of its pma filings.the fda had received a number of reports in which the balloon deflated but was difficult to remove,in some cases because the balloon was stuck to the distal end of the stent.
this issue,known as sticky stent,was different from the problem and was caused by the fact that the taxus stent,unlike the express stent,was coated with a polymer containing a drug that could make the balloon feel stuck to the stent.bsc had became aware of this issue in,when it launched taxus outside of the united states and received many complaints about it.during the months following the launch outside the united states,bsc found that the complaints about this issue subsided as physicians became familiar with the sticky feel of the stent and learned,through bsc training and experience,how to work with it.
during bsc first quarter analyst conference call on april,paul laviolette,senior vice president at bsc,was asked about the sticky stent issue.an analyst with bank of america securities asked if laviolette had any thoughts on why we are hearing this occur in the,while over the last months we did hear much about this occurring in europe.laviolette replied that bsc had received similar complaints internationally when taxus launched in,but that once physicians became accustomed to using taxus,essentially all complaint activity subsided.he said that if you look at international utilization today,and if you look at complaints for any kind of removal difficulty,there are virtually no ongoing complaints,and that this confirms for us what we understand about this particular issue,which is that there are some things to get used to.he also stated that were no discussions related to any kind of field action.
on april,the boston globe reported that bsc had received reports of difficulty implanting taxus stents.the article differentiated between the sticky stent and problems,reporting a boston scientific spokesman said that in most of the reported cases the balloons seemed to stick to the coating of the stent,creating a potential blockage.in about six of the cases the balloon would deflate,or would only deflate slowly.it also reported 
boston scientific spokesman paul donovan said the number of problem cases was minor relative to the taxus stents implanted in american patients since the fda approved the device march.he said a few doctors in europe reported similar problems when taxus was initially approved for use there last year,but the complaints ended as doctors became more comfortable with the stents.
on april,the wall street journal also reported on these reports of difficulties with taxus 
boston scientific said it has received reports of difficulties removing or deflating the balloon used in the angioplasty.but it knows of no deaths or complications due to the issue.it adds that it believes the problem will disappear once physicians gain experience using the taxus.
this sort of thing does tend to happen as physicians gain experience with the device,said company senior vice president paul laviolette.
the article also reported that c opies of of these reports reviewed by the wall street journal showed that most of the complaints appeared to be minor annoyances,requiring the doctor to fiddle a bit to remove or deflate the balloon.
on april,goldman sachs released a report reiterating its buy rating for bsc,explaining that it had conducted a review of the most recently available adverse event reports mdr for the taxus stent in the fda database and conclude d that the nature of the adverse events is within the scope of what can be expected in the early stages of a new interventional product launch.it reported that the current rate of adverse events on a worldwide basis is extremely rare at or per cases and explained that although there is a tendency for of events we believe that the event rate is so low that even with there is no significant issue.the report stated that goldman sachs had been in extensive conversations with bsc management,and that management was consistent in its stance that the performance reports are far and few between,and not unexpected in the early stages of a broad launch.
in the meantime,progress continued on the laser weld shift,and on may,the fda approved the special pma supplement for taxus and express with an order which was publicly available on its website stating that bsc had approval to implement the addition of an additional inspection,modification of a current inspection,and modification of a manufacturing process to address complaints related to failure of the delivery system balloon to properly deflate following stent deployment.bsc began to implement these changes immediately.
the day that the fda approved these changes,they were reported in a merrill lynch analyst report stating that bsc had a manufacturing fix to address the issue of no deflates submitted to the fda to further reduce dependence on operator technique.two days later,the boston globe ran a story that covered both this manufacturing solution to the problem,as well as the sticky stent issue.as to the problem,the article stated 
t o prevent the problem of balloons failing to deflate,boston scientific is making a small change in the process it uses to join the balloon and catheter before the stent is packaged around them,said spokesman paul donovan.the change will not affect the company earnings and wo lead to a recall of any of the thousands of taxus packages that have been shipped but not implanted,he said.
as the article makes clear,donovan differentiated between the and sticky stent issues,explaining that the manufacturing change is meant to address the problem of balloons failing to deflate,while the company has no plans for manufacturing changes to address the other problem.the article reported that the company believes the withdrawal problems are probably because of doctors unfamiliarity with the new system.
on may,bsc learned that a patient had died due to complications from.and in early june,bsc received a complaint on one taxus production lot for which there was a report of a previous failure.the remaining inventory for this batch was retrieved from the warehouse and a pir update was commenced.
while the pir update was ongoing,a june dow jones newswires article about taxus reported that some doctors had experienced a stickiness that makes it somewhat difficult to withdraw auxiliary equipment after the stent is inserted,and that there had been a smattering of reports of patients undergoing emergency surgery to deal with complications that arose during procedures with the stent.the article stated these issues will work themselves out once physicians get used to the product,the company says,and it recently made a manufacturing change to deal with one problem doctors cited.the article quoted paul donovan,spokesman for boston scientific,as saying we had a similar experience in europe where there was a learning curve early on and some initial problems,and then people got used to the product and the number of complaints subsided and the issue went away.the article then went on to more clearly differentiate between the issue and the stickiness issue,stating problems doctors have reported with taxus include trouble getting the balloon to deflate and difficulty withdrawing the balloon catheter.boston scientific is making a change in its manufacturing process that will result in the balloons deflating more easily,donovan said.the article also quoted one doctor as saying that he had not seen any taxus devices that would not deflate,but that he experienced stickiness of the time.it quoted multiple doctors saying that with practice,the stickiness issue was not a problem.the article also reported donovan as saying that t here wo be a recall and describing the number of complaints as tiny.
on the evening of june,the pir team investigating the lot of taxus issued a pir reporting three field complaints and four failures where the devices had become focally necked during manufacturing for this lot.it reported that an examination of all remaining taxus devices in the warehouse from lots manufactured adjacent to this lot found no problems.the pir team recommended recalling the one lot.this recommendation was sent to the field action committee,which after conducting its review,decided on june to institute the recall.
on june,an email from bsc regulatory affairs vice president russell felkey reported that he had spoken with someone at the fda who inquired why bsc is conducting a field action to remove product remaining in the field that was manufactured prior to our pma supplement that included corrective action for.felkey explained that he had told the fda that the company was prepared to discuss this possibility fully,but that he had not disclose d the pending recall since we have fully completed the approval process.
on july,bsc advised the fda that it would be recalling the maple grove lot identified in the june pir.later that day,it received a report from galway that it also had a lot with multiple failures.bsc informed the fda of this,and on july,it recalled both lots.
during a july conference call with analysts,ceo jim tobin explained that the recall affected only two batches out of about that we produced so far,emphasizing we learned a lot from this that will help us avoid a repeat as we go forward.when asked if the company was completely positive that the problem was only in the two lots that were recalled that there might not be another lot out there that has maybe a couple of stents that had the same problem,he replied 
you ca be completely sure until all of the work has been done to investigate every complaint.there will undoubtedly be more complaints that are somewhere in the pipeline,so there are still investigations to go,but those would be single batch,small number kind of situations based on what we think we know today.
he explained that the complaints were from lots produced before the introduction of the laser shift and that there had not yet been any complaints from devices manufactured after the manufacturing change,but emphasized that this does mean we wo.management made clear that there had only been of the newer devices shipped,so that if these lots had a problem at the same rate we been having,you would have expected maybe zero or one,two at the most.we have had any.what does that tell you nothing,because the sample is too small.
when asked how many change lots were in circulation,tobin stated i do know the number of lots,but the number of units is probably in the range somewhere around there.he stated that he did not believe that the limited recall was a tip of the iceberg sort of situation,but it is what it is.tobin explained we looking at those batches for which we have complaints,which is batches,or some number like that,out of.of those,these two we not happy with and we pulling them back.the analysis is not complete,so it is possible that you would find another batch or two,but unlikely,i would say.
in discussing the laser shift,vice president and cfo larry best explained that the company had received complaints of since it launched express,that the company had been working on this for quite a while,and that the manufacturing change was in process before we launched taxus and would have been submitted whether we got a complaint or not.he later emphasized this is not a fix that being made in response to the taxus launch or the taxus complaints.
market analysts labeled the july recall a minor event.a july goldman sachs report stated in our opinion,the recall is a minor issue,which should have a negligible impact on the company market position based on management comments,we believe that the issue has already been resolved and the recall is a remnant of a prior manufacturing process.it explained 
the company indicated that there are only complaints worldwide out of which could not be replicated about the balloon deflation issue with taxus stent system out of the more than stents which have been implanted worldwide,which implies an incidence rate of.fda has received reports of one death and serious injuries associated with balloon deflation and reports of balloon malfunction that were not associated with patient injury,out of more than stents implanted,implying an incidence rate of.these extremely low event rates suggest that the incidence of is a rare occurrence even with and not likely to grow to be a larger issue.
similar details and evaluations were reported in a harris nesbitt analyst report on july.
following the recall,bsc continued its investigation,as jim tobin stated it would in the july conference call.examining all devices remaining in inventory from any batch that had even a single complaint,a team at maple grove made two discoveries.first,it found that by using laser pixel software that recorded detailed information regarding the precise location of the laser for each batch of catheters,it could identify lots in which a laser event affecting the laser alignment,as measured by pixel shifts,made the laser bonds more susceptible to tensile forces.second,it found that the cone puffing process in particular,the sliding of a protector over the stent prior to puffing could create significant tensile forces on the distal outer when the balloon was atypically large,and that cone puffing was a large differentiator between taxus and express with respect to issues.this was the first time that cone puffing was conclusively identified as a cause of.cone puffing had not been used in the manufacture of express,nor in the manufacture of taxus for sale outside the united states.the director of process development in research development at maple grove,phil ebeling,characterized the two discoveries as epiphanies or aha moments for him and his team.
based on these two discoveries,bsc instituted another recall on july.this recall focused on devices that had been produced prior to the implementation of the reticle inspection in april.using laser pixel and cone puffing data for the inspection lots at maple grove,it was able to identify eight lots at risk for focal necking.in galway,however,bsc did not have the laser software being piloted in maple grove,so as a precaution,it decided to recall all taxus devices that had been manufactured at galway prior to the introduction of the reticle inspection.
the recall covered of the more than taxus devices that it had shipped in a press release announcing this recall,bsc explained that in total,it had received reports of one death and eighteen serious injuries associated with balloon deflation failure with taxus devices the press release stated the company implemented review of its manufacturing process,additional inspections,and an modification to the manufacturing process for these products.the current and future production are not expected to experience similar balloon deflation problems.the press release also stated that bsc expected the recall to impact its second quarter financial results,including a reversal of million in sales and a of million in inventory.
following the announcement of the expanded recall,bsc stock price dropped.plaintiff claims the investing shareholders represented by the class lost over million 
our review of a grant of summary judgment is de novo.city of dearborn heights act police fire ret.waters,cir.summary judgment is required when the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.c.
a.the elements of securities fraud 
for plaintiff to prevail on its claim that defendants violated section b and rule,it must prove six elements a material misrepresentation or omission scienter,or a wrongful state of mind a connection with the purchase or sale of a security reliance economic loss and loss causation.waters,at.this case turns on the second of these requirements,scienter,and the question of whether plaintiff has produced sufficient competent evidence that defendants acted with scienter to survive their motion for summary judgment 
scienter is an intention to deceive,manipulate,or defraud.ernst ernst hochfelder,see also sec ficken,cir.under this circuit precedent,proving scienter requires a showing of either conscious intent to defraud or a high degree of recklessness.aca fin.guar.advest,cir quoting aldridge cross,cir.recklessness in this context means a highly unreasonable omission,involving not merely simple,or even inexcusable negligence,but an extreme departure from the standards of ordinary care,and which presents a danger of misleading buyers or sellers that is either known to the defendant or is so obvious the actor must have been aware of it.sec fife,cir quoting greebel ftp software,cir internal quotation marks omitted.
although this case turns on scienter,it is important to identify the related requirement of materiality.see bsc i,at knowingly omitting material information is probative,although not determinative,of scienter.as the supreme court recently stated in matrixx initiatives,siracusano,the materiality requirement is satisfied when there is a substantial likelihood that the disclosure of the omitted fact would have been viewed by the reasonable investor as having significantly altered the total mix of information made available.id.at quoting basic levinson,internal quotation marks omitted.
the court explained that it was careful not to set too low a standard of materiality,for fear that management would bury the shareholders in an avalanche of trivial information.id.quoting basic,at.but at the same time,the court rejected the use of a bright line rule that reports of adverse events associated with a pharmaceutical company products can not be material absent a sufficient number of such reports to establish a statistically significant risk that the product is in fact causing the events.id.at.the court explained that because medical professionals and regulators act on the basis of evidence of causation that is not statistically significant,it stands to reason that in certain cases reasonable investors would as well.id.at.
the court cautioned,however,that it was not holding that all adverse events must be disclosed.it stressed that rule and section b do not create an affirmative duty to disclose any and all material information.id.it explained that disclosure is required under these provisions only when necessary to make statements made,in the light of the circumstances under which they were made,not misleading.id.quoting b b see also basic,at silence,absent a duty to disclose,is not misleading under rule.the court explained that e ven with respect to information that a reasonable investor might consider material,companies can control what they have to disclose under these provisions by controlling what they say to the market.matrixx.at.
plaintiff proposed inference of scienter 
we understand plaintiff case to rest in general on the claim that the defendants were aware of a risk that problems with taxus devices would require a significant recall that the company statements and omissions misled the market about the nature,cause,and degree of this risk and that these facts support an inference that defendants acted with scienter.specifically,plaintiff argues that a reasonable inference of defendants scienter is established by evidence that on three issues,defendants had knowledge of facts or access to information contradicting their public statements.evidence that defendants published statements when they knew facts suggesting the statements were inaccurate or misleadingly incomplete is classic evidence of scienter.aldridge,at.here,however,plaintiff evidence considered individually and as a whole makes clear that no reasonable jury could find that defendants recklessly misled the market about a significant risk of taxus or the need for a recall,much less that they intentionally did so.
disclosure of the laser shift 
plaintiff argues that defendants failure to implement the planned laser shift in november recklessly created a significant risk that the newly launched taxus devices would need to be recalled and is evidence that defendants acted with scienter in not disclosing the existence of the fix sooner than they did.
at its core,this argument rests on the premise that the laser shift was not only the ultimate solution to the problem of focal necking,but also the criterion that defined whether or not a device needed to be recalled.this premise is flawed for a number of reasons.first,there is no evidence that the laser shift was itself sufficient to prevent focal necking in taxus the fall conclusion by the six sigma team that the laser shift would prevent focal necking for express regardless of other causal factors did not apply to the causal factor of cone puffing,as cone puffing was not used in the manufacture of express and its relevance to focal necking in taxus was not known until the summer of.second,the implementation of the laser shift was not a determinative criterion in the recall.
the july,decision about which lots of taxus to recall was not based on whether they had been produced using the new laser alignment.rather,the decision was based on whether the lots had been produced before or after the introduction of the reticle inspection at the end of april.the recall covered all devices that were manufactured before this,and none that were manufactured after it.likewise,no devices manufactured in maple grove after this were recalled.while bsc was able to limit the recall of maple grove lots manufactured inspection by using manufacturing data not available in galway,the introduction of the reticle inspection was nevertheless the defining moment in time.therefore,although the laser shift was a manufacturing solution to focal necking that eliminated the need for some of bsc other solutions,it was not determinative of whether a product needed to be recalled 
plaintiff nevertheless contends that defendants were required to disclose the laser shift sooner than they did.it claims that bsc was prepared to submit its change to the fda by november,but that the process was aborted by the taxus pma council in order to keep the taxus release on schedule,thereby misleading the market about the risk that it would be introducing a new product that had a manufacturing defect.it argues that the decision to build inventory without the permanent fix in place made the recalls not just foreseeable,but probable.
there is no evidence in the record that supports this claim.the evidence is that as of november,bsc had not validated the mm laser shift and was not prepared to submit this documentation to the fda,as it needed to do before implementing the change.although plaintiff is correct that on september,the engineer leading the laser shift team,kevin griffin,proposed a validation plan for the laser shift that would be completed and submitted to the fda by november,the email to which griffin attached this plan also stated that it was a bit optimistic.likewise,while six sigma team leader peter delmer testified that the laser shift had been confirmed as a manufacturing solution to focal necking by october,he also testified that at this point,an awful lot more work would have to be done in order to implement the manufacturing change.further,the additional work that griffin and delmer said was required was in fact done.in october,the team had only recommended shifting the laser from mm to mm,rather than the mm position that was ultimately implemented.it would have been inappropriate for the company to disclose that it was considering a manufacturing change before it was satisfied that the change would not itself cause other problems,and no inference of scienter can be drawn from this.
moreover,griffin validation plan was created for express not taxus a fact that plaintiff ignores in arguing that the taxus pma council modified the plan.although both the express and taxus systems were built using the same catheter,the teams worked independently and plaintiff cites no evidence that the validation plan and fda submissions for express were influenced by the taxus pma council decision to only allow critical modifications to the taxus pma after october on the contrary,when griffin sent the validation plan to paul bulger and asked whether he should keep the taxus reg folks involved,bulger replied i have informed taxus regulatory of the proposed changes.they have not given any specific feedback or concerns.since this is a change to the delivery system only,it should have a minimal impact to the taxus pma review.
moreover,no inference of scienter can be drawn from the fact that bsc management decided at the end of november that it did not immediately need to disclose or implement the laser shift.at this point,there had been only two complaints for the tens of thousands of express and taxus devices manufactured at galway after the introduction of the may changes,and there had been only three ever on express devices manufactured at maple grove.based on the information available,no inference of scienter can be drawn from defendants conclusion that the preventive measures implemented in may had been effective in further reducing what was already,by industry standards,a very low rate of complications.
plaintiff also claims that later,in the march may time period,no defendant affirmatively disclosed any information about the approval of manufacturing changes and the fact that some change inventory remained in the field.however,it is clear that the market knew that bsc was implementing a manufacturing change to address on may,when the fda approved the special pma supplement requesting permission to make the change.the fda approval,which was publicly available on its website,informed the market that bsc was making a modification of a manufacturing process to address complaints related to failure of the delivery system balloon to properly deflate following stent deployment.the change was also reported later that day in a merrill lynch analyst report,which stated that the company was implementing a manufacturing fix to address the issue of no deflates.it would have been clear to the market that the stents produced prior to this date did not incorporate this modification.
statements regarding physician unfamiliarity 
plaintiff also claims that from april through the july recall,bsc misled and lulled the market by maintaining that the problems with taxus were due to physician unfamiliarity with the device,rather than a manufacturing issue,and that o nly after the recalls did bsc admit that the defect in the catheter was manufacturing related.plaintiff has produced no evidentiary support for its claim,having often conflated the problem with the sticky stent problem and failed to differentiate between the problems and their causes.
plaintiff claims that senior vice president paul laviolette misrepresented the cause of problems with the stent system,and lulled the market,when he said during the first quarter analyst conference call on april,that essentially all complaint activity subsided as physicians became accustomed to using taxus.this statement was in response to a specific question in which an analyst asked about the sticky stent problem not the problem and why there had been no reports of such a problem in europe over the past months.laviolette explained that there had in fact been sticky stent complaints when taxus was first launched in europe,but that these complaints subsided as physicians became accustomed to using taxus.he did not say that physician technique was the cause of the problem.
plaintiff also focuses on statements by bsc spokesman paul donovan,who was reported in a boston globe article on april as saying that a few doctors in europe reported similar problems when taxus was initially approved for use there last year,but the complaints ended as doctors became more comfortable with the stents.this was true as to the sticky stent problem,and as the article reported,donovan differentiated between the two problems.in discussing the complaints that had been received,he explained that in most of the reported cases the balloons seemed to stick to the coating on the stent,creating a potential blockage.in about six of the cases the balloon would deflate,or would only deflate slowly.
it is true that not every article was as clear in differentiating between the complaints,but no inference of scienter can be drawn from this fact.plaintiff cites an april wall street journal article that stated 
boston scientific said it has received reports of difficulties removing or deflating the balloon used in the angioplasty it adds that it believes the problem will disappear once physicians gain experience using the taxus.this sort of thing does tend to happen as physicians gain experience with the device,said company senior vice president paul laviolette.
even so,the article went on to state that c opies of of these reports reviewed by the wall street journal showed that most of the complaints appeared to be minor annoyances,requiring the doctor to fiddle a bit to remove or deflate the balloon,apparently referring to the same of complaints reported in the boston globe article.the fact that this wall street journal article was not as clear as the boston globe in reporting that there were two different issues and sticky stent and that physician familiarity solved the latter,does not support a claim that defendants recklessly misled the market as to the cause of the complaints.this is especially so given that reports and statements issued over the next month clearly noted the different problems and solutions.
on may,the market had clear notice that bsc was not attributing the problem to physician mishandling when the fda announced approval of bsc request for a modification of a manufacturing process to address complaints related to failure of the delivery system balloon to properly deflate following stent deployment.the day that the fda approved the change,it was reported in a merrill lynch analyst report stating that the company has a manufacturing fix to address the issue of no deflates submitted to the fda to further reduce dependence on operator technique.and two days later,the boston globe ran a story that covered both the solution to the issue,as well as the sticky stent problem.as to the issue,the article stated t o prevent the problem of balloons failing to deflate,boston scientific is making a small change in the process it uses to join the balloon and catheter before the stent is packaged around them,said spokesman paul donovan.the article makes clear that donovan differentiated between the and sticky stent issues,and their solutions,explaining that the manufacturing change is meant to address the problem of balloons failing to deflate,while the company has no plans for manufacturing changes to address the other problem,which was sticky stent.likewise,a may,goldman sachs report stated that the worldwide rate of withdrawal resistance balloons sticking to the stent is only,which has largely been controlled through additional physician training,while other issues,including the worldwide rate of deflation difficulty balloons unwilling to deflate following dilatation,were corrected with slight adjustments implemented to the balloon catheter.
that physician experience and technique could solve complaints of stent stickiness continued to be clearly reported to the market in the following month.on june,a dow jones newswires article stated problems doctors have reported with taxus include trouble getting the balloon to deflate and difficulty withdrawing the balloon catheter.as to the former,it noted that boston scientific is making a change in its manufacturing process that will result in the balloons deflating more easily.it quoted one doctor as saying that he had not seen any taxus stent systems that would not deflate,but that he experienced stickiness with them of the time.it also quoted multiple doctors saying that with practice,the stickiness issue was not a problem 
given that market analysts and bsc management regularly differentiated between the two problems and their causes,there is no basis for plaintiff contention that e ven on july,after the first recall,market analysts continued to believe that doctors techniques were the problem behind.in fact,the july,merrill lynch analyst report that plaintiff cites in support of this claim contradicts it.the report highlighted the manufacturing solution to the problem of,explaining that bsc identified a series of manufacturing events that increased the risk of that the recall was based on these manufacturing lots and that bsc had introduced a manufacturing change in may that is meant to further reduce the incidence of no deflates.the report only reference to the role of physician handling was a single sentence that noted that bsc was sending a letter to physicians to inform them of handling issues that can prevent or mitigate complications with.this does not blame physicians for the problem.rather,it says that physicians could be part of a solution that was being primarily achieved through a manufacturing change.
statements regarding recall risk 
plaintiff claims that the july recalls were foreseeable and that bsc should have disclosed the risk sooner.they state that a recall of taxus was not merely in the universe of risks recognized by defendants,it was a certain risk known to the defendants,thus transforming this case from one of mere negligence to one of deliberate indifference.plaintiff proposed inference of scienter is not only based on what defendants failed to say about the introduction of the laser shift,discussed above,but also on what they did say about the risk of recall.plaintiff argues that defendants affirmatively misled the market about this risk.
plaintiff claims that starting in april,bsc told the market that there would be no recall of devices manufactured prior to the implementation of the manufacturing change,and that e ven on june,the date the company had determined a recall was necessary,the company continued to make statements that there would be no recall.the evidence does not support these claims.
plaintiff points to the fact that a june dow jones newswires article reported paul donovan as saying there would not be a recall,while a june pir recommended the recall of one batch of taxus devices manufactured in maple grove.however,the pir was not completed until the evening of june,while the article was published in the morning.it is also unclear from the article when donovan made this statement.further,standard company protocol required that pir recommendations be evaluated and approved by the fac,and the fac did not make its final decision to institute the recall until about a week later on june.
plaintiff also argues that ceo jim tobin misrepresented the known risk of a second recall when,during the analyst call on july,he said that he did not believe that the recall was a tip of the iceberg sort of situation.plaintiff argues that this statement is inconsistent with an email that tobin sent earlier in the day in which he mentioned that he was not totally confident that everything was under control,expressing concern that he had just learned that twenty more lots were being tested in galway.
the two statements are not inconsistent and do not support an inference of scienter.subsequent emails made clear that the company was assessing the risk of receiving additional complaints on the twenty lots for which there had been only one complaint,and was not in fact testing any of these devices in these lots.further,plaintiff fails to note that tobin expressly discussed this during the conference call.in response to a question about future recalls,tobin explained we looking at those batches for which we have complaints,which is batches,or some number like that,out of.of those,these two we not happy with and we pulling them back.the analysis is not complete,so it is possible that you would find another batch or two,but unlikely,i would say.
during the july conference call,tobin even expressly identified the risk that there could also be complaints for the lots produced after the introduction of the laser shift.he explained that bsc had not received any complaints about devices manufactured after the introduction of the laser shift,but emphasized that this does mean we wo.this discussion with analysts made clear that because only shift devices had shipped,and the historical rate of error was very low,the fact that there had been no complaints so far meant n othing,because the sample is too small.defendants were clear about the risk of another small recall 
there is no evidence that management had reason to suspect a recall on the order of the second recall,much less that they recklessly or intentionally misled the market about it,such as to permit an inference of scienter.rather,the evidence is that it was not until after july that the company recognized the significance of the factors that provided the basis for the second recall.defendants testified that it was not until after the first recall that the company recognized that the cone puffing process was creating tensile forces on the devices significant enough to cause,and plaintiff fails to identify any evidence that draws this testimony into question.
plaintiff argues that defendants account of when they learned of the role of cone puffing is contradicted by an internal report circulated on march,stating that the loading of the balloon protector after folding and after cone puffing has been highly suspected as a source of high tensile forces during processing.but plaintiff fails to note that the report then states but we have not been able to draw direct correlation to focal necking and concludes that additional research activities need to be started to assess the tensile forces that are being applied at various processes balloon folding cone puffing.
plaintiff also argues that defendants account of the role of cone puffing in and the recall is contradicted by an email from bsc engineer ken pucel on august,stating that there was too much uncertainty to draw a definitive conclusion about whether cone puffing was causing the for taxus.however,pucel email also stated that there is good reason to suspect conepuffing,noting that galway complaint rate increased from ppm to ppm after the introduction of cone puffing and concluding that the company need ed to have a six sigma black belt further analyze the data.even if this august email indicated what defendants knew in early july,rather than late august,it would do nothing to undermine defendants evidence that the second recall was instituted in part because of new information they learned about the risk of focal necking due to cone puffing 
c.the grant of summary judgment 
in considering defendants motion for summary judgment,we must look at the record in the light most favorable to plaintiff and indulge all reasonable inferences in its favor.evans cabinet kitchen int l,cir.plaintiff,however,must nonetheless put forth specific facts to support the conclusion that a triable issue subsists.martnez rodrguez guevara,cir.evidence that is merely colorable or is not significantly probative can not defeat the motion.anderson liberty lobby.with respect to each issue on which plaintiff has the burden of proof at trial,it must present definite,competent evidence to rebut the motion,martnez rodrguez,at quoting vineberg bissonnette,cir internal quotation marks omitted,and as our review of the facts and plaintiff claims makes clear,plaintiff has failed to produce evidence that would support a reasonable inference that defendants acted with scienter.
a statement or omission is only actionable if,at the relevant time,defendants knew,or were reckless in not knowing,of material information that they were obligated to disclose and acted intentionally or recklessly in failing to disclose it.see carpenters pension annuity funds biogen idec,cir see also aca,at statements were not materially misleading where there was nothing to establish that the defendants were aware of facts,at the time they made their predictions,that would have made those predictions unreasonable bsc i,at securities actions raise questions of what corporate managers knew and when they knew it.
as to the laser shift,the key issue is not whether defendants were aware that the change was being contemplated,as plaintiff suggests,but rather whether they were aware or recklessly unaware that the problem threatened taxus viability and hence the price of bsc stock.see detroit ret.medtronic,cir t he material question is whether the medical devices were known to exceed acceptable failure rates overall.in re carter wallace,sec,cir focusing on whether defendants had sound reason to doubt the commercial viability of product backman polaroid,cir en banc distinguishing between allegations of commercial failure and allegations of undisclosed details relating to risks see also biogen idec,at.plaintiff did not produce evidence that would support a reasonable inference that defendants intentionally or recklessly misled the public about such a risk.
a company does not commit securities fraud merely by failing to disclose all material information that it possesses.aca,at.disclosure is required only when necessary to make statements made,in the light of the circumstances under which they were made,not misleading.b b matrixx.at.given the statements and disclosures that defendants did make,they had no obligation to disclose the fact that they were working on an improvement that would reduce the very small number of complaints that they received,and of which the market was aware.geffon micrion,cir finding that although the defendant could have provided still more information regarding an alleged omission,its failure to do so does not mean that the omission was purposely deceptive in a manner actionable under rule.
the investing public was not only aware of the complaints,but also of the risk of recall,which defendants openly discussed.to the extent that the plaintiff complaint is that the precise degree of risk was not stated,that failure is not sufficient to have rendered the statements misleading.hill gozani,cir emphasis added.
while a statement of risk does not insulate the speaker from liability neither does it create liability simply because it does not disclose,at the level of detail the plaintiffs request in retrospect,all of the factors that contribute to the risk assessment.see also backman,at company disclosure that product was being sold below cost need not say how much below or that sales were below expectations.as we stated in hill,where the level of risk is unknown and the existence of a risk is disclosed,we shall hesitate to conclude that disclosure is misleading merely because it did not state that the risk was serious.hill,at.
our conclusion as to scienter does not change when we consider plaintiff insider trading claims.waters,at biogen idec,at.insider trading can not establish scienter on its own,but rather can only do so in combination with other evidence.bsc i,at.no such evidence exists here.while there were stock trades during this period,they did not suggest there was trading based on insider information.we agree with the district court that the nature and circumstances of defendants trades would not in any event support an inference of scienter for the reasons the court identified.see in re boston sci,d at.
because plaintiff failed to produce evidence that would support a reasonable inference that defendants acted with scienter,the district court properly granted defendants motion for summary judgment on the section b and rule claims.because plaintiff section a claim was derivative of the rule claim,it was properly dismissed as well.see a,waters,at.
in addition to appealing the district court grant of defendants motion for summary judgment,plaintiff appeals the court denial of its motion to compel production of certain documents that defendants claimed were privileged.almost all of these documents were generated in connection with an internal company investigation of the july recalls that was instituted in late august at the request of bsc general counsel,paul sandman,in response to inquiries by the sec and doj.the district court reviewed these documents in camera.concluding that they were protected by either or both privilege and work product privilege,it denied plaintiff motion to compel production 
when an appeal concerns a claim of privilege,the standard of review depends on the precise issue being litigated.in re keeper of records grand jury subpoena addressed to xyz,cir.we review a district court evidentiary decisions for abuse of discretion,its underlying findings of fact for clear error,and questions of law de novo.id.the fact that the district court did not provide a detailed account of its reasoning does not change the standard.id.at.
privilege protects communications made in confidence by a client and a client employees to an attorney,acting as an attorney,for the purpose of obtaining legal advice see upjohn united states.by safeguarding communications between client and lawyer,the privilege encourages full and free discussion,better enabling the client to conform his conduct to the dictates of the law and to present legitimate claims and defenses if litigation ensues.in re keeper of records,at.
plaintiff argues that accidentally disclosed documents from bsc internal recall investigation working group riwg reveal that its investigation was a on the recall to help the company avoid similar problems in the future and was unrelated to the provision of legal advice.the fact that communications between the riwg and bsc attorneys focused on ways to prevent similar mistakes in the future does not,however,remove them from privilege.on the contrary,this type of information was highly relevant to bsc potential liability and consequently directly related to providing legal advice to bsc management 
plaintiff also argues that defendants funneled documents unrelated to legal advice through attorneys to cloak the documents with a claim of privilege,citing accidentally disclosed documents showing that riwg members were instructed to and did send written communication to each other through bsc general counsel and counsel.in taking steps to protect privilege such as telling the riwg that all written communication should go through bsc attorneys and that riwg members should not directly write to each other bsc general counsel did not manufacture privilege but rather protected it when the communications were made for the purpose of providing requested legal advice.upjohn,at employees were given explicit instructions by company management to treat communications as highly confidential by not sharing them with others during an investigation directed by counsel.
there is nothing in the documents that plaintiff identifies or in the confidential documents that we have reviewed that provides a basis for reversing the district court denial of plaintiff motion to compel their production.
we affirm entry of judgment for defendants.costs are awarded to defendants.
first,it held that the evidence regarding defendants statements,omissions,and stock sales did not support a reasonable inference that they acted with scienter in not disclosing or implementing the manufacturing fix or recalls sooner,and that rather than lulling the market,defendants had made a reasonable effort to address the risks inherent in the launch of taxus.second,the court held that no reasonable jury could find that any of the alleged misrepresentations by the defendants were material because the market had available sufficient corrective information to cure any arguably misleading statements or omissions.third,the court held that in light of the timing of bsc disclosures regarding the complaints and its manufacturing solution,there was insufficient evidence to support plaintiff claim that the alleged misrepresentations caused plaintiff economic losses.first,it held that the evidence regarding defendants statements,omissions,and stock sales did not support a reasonable inference that they acted with scienter in not disclosing or implementing the manufacturing fix or recalls sooner,and that rather than lulling the market,defendants had made a reasonable effort to address the risks inherent in the launch of taxus.second,the court held that no reasonable jury could find that any of the alleged misrepresentations by the defendants were material because the market had available sufficient corrective information to cure any arguably misleading statements or omissions.third,the court held that in light of the timing of bsc disclosures regarding the complaints and its manufacturing solution,there was insufficient evidence to support plaintiff claim that the alleged misrepresentations caused plaintiff economic losses.
a may update reported,rather than twenty,on galway express devices,accounting for a complaint that was reported on may.a may update reported,rather than twenty,on galway express devices,accounting for a complaint that was reported on may.
the fac also directed that it be provided with updates regarding and the effectiveness of the preventative actions recommended in the pir.in addition,the pir team updated its analysis on june,july,and october,each time concluding that no field action was warranted.the fac also directed that it be provided with updates regarding and the effectiveness of the preventative actions recommended in the pir.in addition,the pir team updated its analysis on june,july,and october,each time concluding that no field action was warranted.
eventually,in december,galway resumed manufacturing its own distal outers.eventually,in december,galway resumed manufacturing its own distal outers.
a weld length that is too long indicates that the device might have been produced with excessive laser heat,thinning the distal outer and making it more prone to focal necking.a weld length that is too long indicates that the device might have been produced with excessive laser heat,thinning the distal outer and making it more prone to focal necking.
six sigma is an engineering methodology that employs mathematics and statistical tools to refine and improve industrial processes.six sigma is an engineering methodology that employs mathematics and statistical tools to refine and improve industrial processes.
an earlier company investigation,completed in november,had identified a laser shift of mm to mm as one partial solution,among several others,to the problem of focal necking.however,the report stated that not all of recommendations needed to be implemented to prevent focal necking,concluding that laser dwell time has the greatest effect and that reducing the energy applied to the bond site will have the most pronounced effect in producing bonds more robust to focal necking.to reduce the chance of a hot weld,the report recommended changes to the matte finish length criteria.such changes were implemented in the spring of.an earlier company investigation,completed in november,had identified a laser shift of mm to mm as one partial solution,among several others,to the problem of focal necking.however,the report stated that not all of recommendations needed to be implemented to prevent focal necking,concluding that laser dwell time has the greatest effect and that reducing the energy applied to the bond site will have the most pronounced effect in producing bonds more robust to focal necking.to reduce the chance of a hot weld,the report recommended changes to the matte finish length criteria.such changes were implemented in the spring of.
griffin circulated another draft of the validation plan on december,and another revised version on february.the research was not completed until the spring.griffin circulated another draft of the validation plan on december,and another revised version on february.the research was not completed until the spring.
larry best also spoke with caution,stating that the people working on the issue were pretty confident that they further reduced any incidence of no deflate,but who knows.larry best also spoke with caution,stating that the people working on the issue were pretty confident that they further reduced any incidence of no deflate,but who knows 
plaintiff contends that this is contradicted by defendants admission during a july call that the laser shift was implemented in reaction to complaints.there is no such contradiction.while the change to express was in response to the complaints,the decision to incorporate it into taxus was based on the fact that taxus used the same express catheter.plaintiff contends that this is contradicted by defendants admission during a july call that the laser shift was implemented in reaction to complaints.there is no such contradiction.while the change to express was in response to the complaints,the decision to incorporate it into taxus was based on the fact that taxus used the same express catheter.
as a further precaution,bsc also recalled express devices that had been manufactured in galway before the introduction of the may changes.it had shipped over express devices.as a further precaution,bsc also recalled express devices that had been manufactured in galway before the introduction of the may changes.it had shipped over express devices.
it also noted that it had received reports of two deaths and serious injuries associated with express devices.it also noted that it had received reports of two deaths and serious injuries associated with express devices.
after the july recall,bsc realized that it had made an error in calculating the manufacture dates for the recall,as the reticle inspection was not in place at galway until days later than it had originally thought.on august,bsc recalled the taxus devices that had been manufactured at galway during this time period.after the july recall,bsc realized that it had made an error in calculating the manufacture dates for the recall,as the reticle inspection was not in place at galway until days later than it had originally thought.on august,bsc recalled the taxus devices that had been manufactured at galway during this time period.
although it is unusual to grant summary judgment on scienter,summary judgment on this issue is sometimes appropriate.even in cases where elusive concepts such as motive or intent are at issue,summary judgment may be appropriate if the nonmoving party rests merely upon conclusory allegations,improbable inferences,and unsupported speculation.sec ficken,cir quoting medina munoz reynolds tobacco,cir.although it is unusual to grant summary judgment on scienter,summary judgment on this issue is sometimes appropriate.even in cases where elusive concepts such as motive or intent are at issue,summary judgment may be appropriate if the nonmoving party rests merely upon conclusory allegations,improbable inferences,and unsupported speculation.sec ficken,cir quoting medina munoz reynolds tobacco,cir.
plaintiff claim that the laser shift was a crucial manufacturing change is further weakened by the fact that it was also irrelevant to the recall of express devices.for express,the recall fence was the may changes.the fact that the determinative date for express was the introduction of the may changes and not the laser shift,or even the reticle inspection also indicates that the causes of focal necking in taxus devices were not,as plaintiff contends,identical to the causes in express devices.this further undermines plaintiff claim that in november,the taxus pma council postponed the implementation of the validation plan for the laser shift on express despite awareness that it was a critical fix.plaintiff claim that the laser shift was a crucial manufacturing change is further weakened by the fact that it was also irrelevant to the recall of express devices.for express,the recall fence was the may changes.the fact that the determinative date for express was the introduction of the may changes and not the laser shift,or even the reticle inspection also indicates that the causes of focal necking in taxus devices were not,as plaintiff contends,identical to the causes in express devices.this further undermines plaintiff claim that in november,the taxus pma council postponed the implementation of the validation plan for the laser shift on express despite awareness that it was a critical fix.
after october,bsc did submit changes to the taxus pma.on november,it submitted a pma amendment notifying the fda of the new elongation specification that it had already incorporated into express.after october,bsc did submit changes to the taxus pma.on november,it submitted a pma amendment notifying the fda of the new elongation specification that it had already incorporated into express.
plaintiff also states that the laser shift was included on bsc submission schedule on october,but no longer on the list on october,due to the council decision.its citations to the record do not support this claim.both lists include the laser shift,and neither has a proposed submission date.plaintiff also states that the laser shift was included on bsc submission schedule on october,but no longer on the list on october,due to the council decision.its citations to the record do not support this claim.both lists include the laser shift,and neither has a proposed submission date.
plaintiff claims that this article also reported that the company had said that problems will work themselves out once physicians get used to the product.emphasis added.this mischaracterizes the article.the relevant text of the article states some doctors say there is extra effort associated with taxus,including a stickiness that makes it somewhat difficult to withdraw auxiliary equipment after the stent is inserted.there have also been a smattering of reports of patients undergoing emergency surgery to deal with complications that arose during procedures with the stent these issues will work themselves out once physicians get used to the product,the company says,and it recently made a manufacturing change to deal with one problem doctors cited.although it is not entirely clear what the author of the article meant by these issues,and this phrase can be read to include the issue,this does not provide a basis for a reasonable inference of scienter,as the rest of the article and many other articles report bsc management as clearly differentiating between the two different issues and their solutions.plaintiff claims that this article also reported that the company had said that problems will work themselves out once physicians get used to the product.emphasis added.this mischaracterizes the article.the relevant text of the article states some doctors say there is extra effort associated with taxus,including a stickiness that makes it somewhat difficult to withdraw auxiliary equipment after the stent is inserted.there have also been a smattering of reports of patients undergoing emergency surgery to deal with complications that arose during procedures with the stent these issues will work themselves out once physicians get used to the product,the company says,and it recently made a manufacturing change to deal with one problem doctors cited.although it is not entirely clear what the author of the article meant by these issues,and this phrase can be read to include the issue,this does not provide a basis for a reasonable inference of scienter,as the rest of the article and many other articles report bsc management as clearly differentiating between the two different issues and their solutions.
in response to another question on this topic,he emphasized this point,stating that the company could not be sure that the problems were only in the two lots that were recalled until all of the work has been done to investigate every complaint.he explained there will undoubtedly be more complaints that are somewhere in the pipeline,so there are still investigations to go,but those would be single batch,small number kind of situations based on what we think we know today.in response to another question on this topic,he emphasized this point,stating that the company could not be sure that the problems were only in the two lots that were recalled until all of the work has been done to investigate every complaint.he explained there will undoubtedly be more complaints that are somewhere in the pipeline,so there are still investigations to go,but those would be single batch,small number kind of situations based on what we think we know today.
this caution was also reported by market analysts.a july report from morgan stanley stated,we believe that it is reasonable to expect that there could be a similar announcement over the next few months potentially pertaining to other batches with similar problems.this caution was also reported by market analysts.a july report from morgan stanley stated,we believe that it is reasonable to expect that there could be a similar announcement over the next few months potentially pertaining to other batches with similar problems.
plaintiff also suggests that bsc misled the investing public about the risk of recall in failing to affirmatively disclose complaints.in fact,bsc reported the complaints to the fda in medical device reporting mdr reports,which were publicly available on the fda website.these mdrs were regularly cited in analyst reports on bsc.for example,on april,goldman sachs released a report reiterating its buy rating for bsc,explaining that it had conducted a review of the most recently available adverse event reports mdr for the taxus stent in the fda database and conclude d that the nature of the adverse events is within the scope of what can be expected in the early stages of a new interventional product launch.it reported that the current rate of